Status:

UNKNOWN

Dielectric Tissue Imaging in Cavotricuspid Isthmus Ablation

Lead Sponsor:

EPD Solutions, A Philips Company

Conditions:

Atrial Fibrillation and Flutter

Eligibility:

All Genders

18+ years

Brief Summary

This is a prospective, single center, non-randomized, open-label, single arm study in which we will gather data and physician input for the assessment and further development of the KODEX - EPD functi...

Detailed Description

This is a prospective, single center, non-randomized, open-label, single arm study in which we will gather data and physician input for the assessment and further development of the KODEX - EPD functi...

Eligibility Criteria

Inclusion

  • Subject must be aged \>18 years.
  • Subject must have signed a written Informed Consent form to participate in the study, prior to any study related procedures.
  • Subject must be willing to comply with the protocol requirements.
  • A female subject is eligible if not of child bearing potential or has a negative pregnancy test within the previous 7 days.
  • Subject is deemed amenable to therapeutic ablation for atrial flutter or atrial fibrillation.

Exclusion

  • Any planned surgical or endovascular intervention within 30 days before or after the index procedure.
  • Subject is enrolled in another drug or device study protocol that has not reached its primary endpoint.
  • Patient had experienced previous stroke (TIA or CVA).
  • Thrombi detected in the heart.
  • Known marked valvular insufficiency (moderate-severe and severe)
  • Life expectancy less than 12 months.
  • Known severe renal insufficiency (stages G4 and G5, characterized by severe reduction in GFR \[15-29 ml/min/1.73 m2\] and GFR \[\<15 ml/min/1.73 m2\], respectively).
  • Subjects that according to the clinical judgment of the caring physician do not fit for the study.
  • Previous right atrial ablation procedure or cardiac ablation procedure performed within 90 days prior to enrollment.

Key Trial Info

Start Date :

July 20 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 30 2022

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT04438395

Start Date

July 20 2020

End Date

June 30 2022

Last Update

May 6 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

NYU Langone Health

New York, New York, United States, 10016